Recombinant Mouse IL-33 Protein

Name: Recombinant Mouse IL-33 Protein
Brand: Beta LifeScience
SKU: BL-1755NP
Availability: InStock

BL-1755NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, Buy cytokines, chemokines, and growth factors for research online, High-purity interleukins & receptors for research, High-quality recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Mouse Interleukin-33 is produced by our E.coli expression system and the target gene encoding Ser109-Ile266 is expressed.
Accession	Q8BVZ5
Synonym	Interleukin 33; IL-33; IL33; C9orf26; NKHEV; Interleukin-1 family member 11; DVS27; NF-HEV and IL- 1F11
Gene Background	Mouse Interleukin 33 (IL-33) is a 30 kDa proinflammatory cytokine which may also regulates gene transcription in producer cells. IL-33 is constitutively expressed in smooth muscle and airway epithelia. IL-33 was identified based on sequence and structural homology with IL-1 family cytokines. It is up‑regulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL-1 alpha or IL‑1 beta stimulation. IL-33 is structurally related to IL-1, which induces helper T cells to produce type 2 cytokines and acts through the receptor IL1RL-1. BindingIL-33 to this receptor activates NF-kappa-B and MAP kinases and induces in vitro Th2 cells to produce cytokines. In vivo, IL-33 induces the expression of IL-4, IL-5, IL-13 and also leads to severe pathological changes in mucosal organs.
Molecular Mass	17.6 KDa
Apmol Mass	18 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, 1mM DTT, pH 7.4.
Endotoxin	Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Biologically active. Please contact us to obtain bioactivity data.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury.; In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets. This form is rapidely lost upon angiogenic or proinflammatory activation.
Subcellular Location	Nucleus.; Nucleus. Chromosome. Cytoplasm. Cytoplasmic vesicle, secretory vesicle. Secreted.
Protein Families	IL-1 family
Database References	KEGG: mmu:77125 STRING: 10090.ENSMUSP00000025724 UniGene: PMID: 29379874 this paper shows that IL-33 promotes gastrointestinal allergy in a TSLP-independent manner PMID: 28656964 our findings demonstrate the critical roles of interleukin 33 in promoting colorectal cancer development through inducing tumor-infiltrating ST2L+ regulatory T cells PMID: 29950152 Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone. PMID: 27697499 Taken together, our data provide the evidence that ST2 deficiency in early phase of sepsis downregulates myeloid precursors, inflammatory NK and dendritic cells PMID: 30001716 data indicate that during acute, resolving colitis, IL-33/ST2 plays a crucial role in gut mucosal healing by inducing epithelial-derived miR-320 that promotes epithelial repair/restitution and the resolution of inflammation. PMID: 30224451 IL-33 may down-regulate CLDN1 expression through the ERK/STAT3 pathway in keratinocytes. PMID: 29534857 the release of IL-33 and GM-CSF from epithelial cells induces the activation of p65 and the p38-MK2/3 signaling module in Dendritic Cells, resulting in Th2 polarization and, finally, allergic inflammation. PMID: 29288203 Injection of IL-21-expressing or IL-33-expressing plasmids facilitates clearance of pre-established genotype B strain designated BPS (BPS) persistence and protects cured mice from BPS re-challenge. PMID: 29242561 In a model of sepsis, IL-33 treatment enhanced the IFN-gamma level in blood and promoted mice's survival, so the protective effects of IL-33 depend on IFN-gamma. The IL-33 treatment also promoted both gammadelta T cells and NK cells in septic mice. PMID: 29610934 VHL-HIF-glycolysis axis is essential for the late-stage maturation and function of ILC2s via targeting IL-33-ST2 pathway. PMID: 29452935 results therefore demonstrate that manipulation of the IL33-NLRP3 axis may be an effective therapy to suppress neuroinflammation and improve the efficacy of antimalarial drug treatment of cerebral malaria. PMID: 29954866 Deficiency of IL-33 was associated with exacerbated atopic dermatitis -like inflammation in Stat6VT mice suggesting at least some aspect(s) of IL-33 signaling could negatively regulate disease in this model. PMID: 29368135 this study shows novel protective mechanism for interleukin-33 at the mucosal barrier during influenza-associated bacterial superinfection PMID: 28401938 IL-33 acts directly on bone marrow ILC2s, making them an early source of IL-5 and part of a process that is central in IL-33-driven eosinophilia. PMID: 28921511 Blockage of IL-33/ST2 axis reduces APAP-mediated organ injury by dampening liver chemokine release and activation of resident and infiltrating liver non-parenchymal cells. PMID: 29032512 these data provide mechanistic insight into how FAK controls the tumor immune environment, namely, through a transcriptional regulatory network mediated by nuclear IL-33. PMID: 29208683 Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis. PMID: 26830114 Results show that interleukin-33 acts to express Schaffer collateral/CA1 long term potentiation (LTP) relevant to spatial learning and memory in a myeloid differentiation factor 88 (MyD88)-dependent manner. PMID: 29147584 IL-33 may induce Th17 cell responses via IL-1beta and IL-6 derived from IL-33-matured dendritic cells. PMID: 28802996 Metaplasia induction and macrophage polarisation after parietal cell loss is coordinated through a cytokine signalling network of IL-33 and IL-13, linking a combined response to injury by both intrinsic mucosal mechanisms and infiltrating M2 macrophages. PMID: 28196875 IL-33/ST2 can induce production of proinflammatory cytokines, such as TNF-alpha and IL-6, through production of IL-13 in Plasmodium chabaudi-infected BALB/c mice, suggesting that IL-33/ST2 play a critical role in inflammatory responses to malaria infection. PMID: 28359899 these results provide new insights into the mechanisms by which intestinal epithelial cells , via IL-33/ST2 axis, may control pro-inflammatory TH17 cells in the small intestine to sustain homeostasis PMID: 28198366 In cells pre-treated with IL-4 and IL-13, expression of mRNA for Ccl3, Ccl5, Ccl17, Ccl24, and Il1b in response to IL-33 stimulation was significantly increased. This was paralleled by up-regulated expression of miR-155-5p, a miRNA that is predicted to regulate several aspects of allergic inflammation. IL-33-activated macrophages may contribute to the exaggerated airway inflammation in exacerbations of allergic asthma. PMID: 29621782 Mice treated with HW for 4 weeks demonstrated a significant decrease in the AD severity score compared with PW-treated mice (p less than 0.01). Hydrogen water administration also significantly reduced TEWL and serum TARC levels (p less than 0.01), infiltration of mast cells (p less than 0.05), and secretion of the proinflammatory cytokines interleukin (IL)-1beta and IL-33 (p less than 0.05) in skin lesions compared wit... PMID: 28889151 IL-33 is necessary for activating Th2-type natural helper cells following respiratory syncytial virus-induced airway inflammation PMID: 28771101 Study found that interleukin33 was critical for repair of aged neurons. Its deficiency caused tau abnormality and late-onset of neurodegeneration in the cerebral cortex and hippocampus, accompanied with Alzheimer's disease-like cognition and memory impairment. PMID: 28675392 this study finds that IL-33 signals primarily to microglia under physiologic conditions, that it promotes microglial synapse engulfment, and that it can drive microglial-dependent synapse depletion in vivo. PMID: 29420261 IL-33 cooperated with Kras and TGFbetaR2 mutations in the development of extrahepatic cholangiocarcinoma (ECC), and anti-IL-33 treatment suppressed ECC development significantly. PMID: 28439013 Data provide clear evidence that IL-33 plays a protective role in trinitrobenzenesulfonic acid-induced colitis, which is closely related to alternatively activated macrophages polarization. PMID: 28423665 Results show that IL-33 is significantly increased in the inflamed skin in urushiol-induced allergic contact dermatitis mice because of increased production and release from keratinocytes. PMID: 27821781 IL-33 production induced by P. gingivalis fimbriae and lipopeptide is recognized by TLR2 and may modulate dendritic cel function in periodontal diseases. PMID: 28637954 CLOCK temporally gates mast cell responses to IL-33 via regulation of ST2 expression. Our findings provide novel insights into IL-33/mast cell-associated physiology and pathologies. PMID: 28259547 results suggest that alveolar Gq/11 signaling maintains alveolar homeostasis and likely independently increases TGFbeta activation in response to the mechanical stress of the epithelium and decreases epithelial IL-33 synthesis. Together, these findings suggest that disruption of Gq/11 signaling promotes inflammatory emphysema but protects against mechanically induced lung injury. PMID: 27811142 Our data indicate that CB2 may directly contribute to the pathogenesis of eosinophil-driven diseases. Moreover, we provide new insights into the molecular mechanisms underlying the CB2 -mediated priming of eosinophils. PMID: 26864308 IL-33 dysregulated lung Treg cells and impaired immunologic tolerance to inhaled antigens PMID: 28196763 gut pericryptal fibroblasts release IL-33 to translate bacterial infection into an epithelial response to promote antimicrobial defense. PMID: 27184849 Mex-3B facilitates the development of allergic airway inflammation by directly upregulating IL-33 expression via inhibiting miR-487b-3p mediated repression of IL-33. PMID: 27545879 IL-33 promoted the new extracellular matrix deposition and angiogenesis formation, which indicates an important role of IL-33 on matrix synthesis and neovascularization. PMID: 28697404 Data indicate that interleukin-33 (IL-33)-induced Interleukin-13 (IL-13) production by type-2 helper T cells (Th2 cells) Is dependent on epidermal growth factor receptor (EGFR) expression. PMID: 29045902 Heligmosomoides polygyrus Alarmin Release Inhibitor (HpARI) prevents binding of active interleukin-33 (IL-33) to the IL-33 receptor. PMID: 29045903 Despite its expression in the synovium of arthritic mice and normal keratinocytes, IL-33 is not required for collagen-induced arthritis development in arthritis or psoriasis PMID: 27317338 The studies establish chronic pancreatitis as an IL-33-dependent inflammation resulting from synergistic interactions between the NOD1 and CCKR signaling pathways. PMID: 26813347 study concludes that IL-33 and TSLP are required for epithelial cell IL-25 expression, mucous metaplasia, and ILC2 expansion following early-life rhinovirus infection PMID: 28701507 Bone marrow-derived mast cells cultured in TGF-beta1, beta2, or beta3 showed reduced IL-33-mediated production of TNF, IL-6, IL-13, and MCP-1 in a concentration-dependent manner. TGF-beta1 inhibited IL-33-mediated Akt and ERK phosphorylation as well as NF-kappaB- and AP-1-mediated transcription. PMID: 28637902 results suggest that EGF is a key growth factor that increased IL-33 production and ST2 receptor expression during intestinal inflammation and carcinogenesis; the EGF/IL-33/ST2 axis represents a novel therapeutic target in colon cancer PMID: 27300306 Lactic Acid Suppresses IL-33-Mediated Mast Cell Inflammatory Responses via Hypoxia-Inducible Factor-1alpha-Dependent miR-155 Suppression PMID: 27559047 Liver Treg cells show a high expression of ST2, a cellular receptor for tissue alarmin IL-33, which is strongly upregulated in the liver of infected mice. These results illustrate the importance of IL-33 in the suppressive function of liver Treg cells during Cytomegaloviruses (CMVs) infection. PMID: 28448566 These data suggest that plasmacytoid dendritic cells producing IFN-alpha and IL-33 play a pivotal role in the chronic fibro-inflammatory responses underlying murine autoimmune pancreatitis and human IgG4-related autoimmune pancreatitis. PMID: 28373582 In vitro IL-33 treatment abrogated MHV-3 and IFN-gamma induced FGL2 expression in RAW264.7 and THP-1 cells. PMID: 28494352

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Mouse IL-33 Protein

Recombinant Mouse IL-33 Protein

Product Overview

Target Details

FAQs